IDH1 and central nervous system cancer: However, the paucity of established preclinical models able to faithfully recapitulate the genetic landscape, tumor microenvironment, and growth patterns of IDH-mutated LGGs has made it extremely challenging for the investigation of the role of IDH mutations in glioma development and progression, and, consequently, of the therapeutic efficacy of IDH inhibitors.